Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT06450197




Registration number
NCT06450197
Ethics application status
Date submitted
8/05/2024
Date registered
10/06/2024
Date last updated
10/06/2024

Titles & IDs
Public title
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
Scientific title
A Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of AZD7798 in Patients With Moderate to Severe Crohn's Disease
Secondary ID [1] 0 0
D9690C00005
Universal Trial Number (UTN)
Trial acronym
AMALTHEA
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Moderate to Severe Crohn's Disease 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Inflammatory bowel disease
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Oral and Gastrointestinal 0 0 0 0
Crohn's disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - AZD7798
Other interventions - Placebo

Experimental: AZD7798 - AZD7798

Placebo Comparator: Placebo - Placebo


Treatment: Drugs: AZD7798
AZD7798

Other interventions: Placebo
Placebo
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
CDAI remission
Timepoint [1] 0 0
Week 12
Secondary outcome [1] 0 0
Endoscopic response
Timepoint [1] 0 0
Week 12
Secondary outcome [2] 0 0
Endoscopic remission
Timepoint [2] 0 0
Week 12
Secondary outcome [3] 0 0
Endoscopic score change from baseline
Timepoint [3] 0 0
Week 12
Secondary outcome [4] 0 0
CDAI response
Timepoint [4] 0 0
Week 12
Secondary outcome [5] 0 0
CDAI score change from baseline
Timepoint [5] 0 0
Week 12
Secondary outcome [6] 0 0
Symptomatic remission
Timepoint [6] 0 0
Week 12
Secondary outcome [7] 0 0
Serum AZD7798 concentration
Timepoint [7] 0 0
Up to 85 days
Secondary outcome [8] 0 0
Incidence of anti-drug antibody response
Timepoint [8] 0 0
Up to 36 weeks
Secondary outcome [9] 0 0
Titre of anti-drug antibody response
Timepoint [9] 0 0
Up to 36 weeks

Eligibility
Key inclusion criteria
1. 18 to 80 years of age.

2. Diagnosis of Crohn's disease established with verifiable clinical, imaging, endoscopic
and/or histopathologic evidence.

3. Moderate to severe active Crohn's disease.

4. Ileal/ileocecal (L1), colonic (L2), or ileocolonic (L3) disease, as classified based
on the localisation of active inflammation.

5. Capable of giving signed informed consent.

6. A history of at least one of:

1. Intolerance or inadequate response to conventional treatment (oral
corticosteroid, azathioprine, 6-mercaptopurine, or methotrexate), biologics, or
other approved advanced therapy (eg, JAK inhibitors) OR

2. Corticosteroid dependency (defined as inability to taper below budesonide 6
mg/day or prednisolone 10 mg/day without recurrent active disease) for the
treatment of Crohn's disease.
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Evidence, or clinical suspicion, of other forms of IBD or concomitant additional
active gastrointestinal luminal inflammatory diseases.

2. Known symptomatic strictures or bowel stenoses or strictures preventing passage of
endoscope throughout the colon.

3. Any complications of Crohn's disease where surgery is anticipated or planned prior to
end of study treatment.

4. Evidence of extensive prior gastrointestinal surgical interventions.

5. Within 3 months prior to screening endoscopy visit:

1. History of toxic megacolon

2. Diagnosis of peritonitis or need for treatment of peritonitis

3. Bowel perforation or evidence of obstruction.

6. Undrained fistula or abscess, including intrabdominal abscesses.

7. Ongoing or expected nutritional dependency on total enteral or parenteral nutrition
during study.

8. Evidence of an increased risk of colorectal cancer.

9. Symptomatic oral Crohn's disease within one year.

10. Any of the following treatments within the specified time period prior to screening
endoscopy visit

1. An anti-TNF biologic within 8 weeks prior to screening endoscopy visit

2. Any biologic targeting immune response other than an anti-TNF within 12 weeks
prior to screening endoscopy visit

3. Other advanced small molecule treatments for Crohn's disease within 4 weeks prior
to screening endoscopy visit

4. Cyclosporine, mycophenolate mofetil, sirolimus (rapamycin), thalidomide, or
tacrolimus (FK-506) within 4 weeks prior to screening endoscopy visit

5. Treatment with apheresis within 4 weeks prior to screening endoscopy visit

6. Administration of any live vaccine within 4 weeks prior to screening endoscopy
visit to end of study

7. Faecal microbiota transplantation within 4 weeks prior to screening endoscopy
visit

8. Lymphocyte-depleting treatment within 12 months prior to screening endoscopy
visit

9. Any previous exposure to AZD7798.

11. Any changes in dosing of the following medications prior to screening endoscopy visit
as outlined:

1. 5-aminosalicylates within 2 weeks

2. Oral corticosteroids within 2 weeks:

(i) Prednisolone (ii) Budesonide (c) Immunomodulators within 4 weeks (d) Antibiotic
therapy for the treatment of Crohn's disease (e) Probiotics within 2 weeks.

12. Known or suspected history of chronic use of nonsteroidal anti-inflammatory drugs.

13. Evidence of recent or currently active infection, including use of IV or oral
antibiotics for documented infection within 30 days prior to screening endoscopy
visit.

14. Evidence of chronic HBV or HCV.

15. History of TB (active or latent) unless an appropriate course of treatment has been
completed.

16. Positive diagnostic TB test at screening.

17. History of serious opportunistic infection within 12 months prior to screening
endoscopy visit.

18. CMV colitis within previous 12 months prior to screening endoscopy visit.

19. Positive C. difficile toxin stool test at screening.

20. Symptomatic herpes zoster infection within 3 months prior to screening endoscopy.

21. Any identified immunodeficiency.

22. Abnormal laboratory results at screening suggesting participation may be unsafe, which
will prevent the patient from completing the study, or will interfere with the
interpretation of the study results.

23. Reproduction:

1. Pregnant and breastfeeding patients, or those planning to breastfeed during the
study

2. FOCBP unless completely abstinent or using a highly effective contraception and
barrier method of contraception.

24. Prolonged QTcF interval.

25. Clinically significant cardiovascular conditions.

26. Current malignancy or history of malignancy.

27. Current significant major or unstable respiratory disease, heart disease,
cerebrovascular disease, haematological disease, hepatic disease, renal disease,
gastrointestinal disease or other major disease other than active Crohn's disease.

28. Current enrolment in another interventional study or treatment with any
investigational drug within 4 months prior to screening endoscopy visit.

29. Unstable lifestyle factors.

30. Patients committed to an institution by virtue of an order issued either by the
judicial or the administrative authorities.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
17/06/2024
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
21/05/2027
Actual
Sample size
Target
192
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - South Brisbane
Recruitment postcode(s) [1] 0 0
QLD 4101 - South Brisbane
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Michigan
Country [2] 0 0
United States of America
State/province [2] 0 0
Texas
Country [3] 0 0
Argentina
State/province [3] 0 0
Buenos Aires
Country [4] 0 0
Austria
State/province [4] 0 0
Klagenfurt am Wörthersee
Country [5] 0 0
Brazil
State/province [5] 0 0
Campinas
Country [6] 0 0
Brazil
State/province [6] 0 0
Curitiba
Country [7] 0 0
Brazil
State/province [7] 0 0
Jaú
Country [8] 0 0
Brazil
State/province [8] 0 0
Porto Alegre
Country [9] 0 0
Brazil
State/province [9] 0 0
Santo Andre
Country [10] 0 0
Brazil
State/province [10] 0 0
São Paulo
Country [11] 0 0
Bulgaria
State/province [11] 0 0
Sofia
Country [12] 0 0
Chile
State/province [12] 0 0
Santiago
Country [13] 0 0
Chile
State/province [13] 0 0
Talcahuano
Country [14] 0 0
Chile
State/province [14] 0 0
Viña del Mar
Country [15] 0 0
Germany
State/province [15] 0 0
Berlin
Country [16] 0 0
Germany
State/province [16] 0 0
Kiel
Country [17] 0 0
Germany
State/province [17] 0 0
Ulm
Country [18] 0 0
Italy
State/province [18] 0 0
Milano
Country [19] 0 0
Japan
State/province [19] 0 0
Chiba-shi
Country [20] 0 0
Japan
State/province [20] 0 0
Hamamatsu-shi
Country [21] 0 0
Japan
State/province [21] 0 0
Kashiwa-shi
Country [22] 0 0
Japan
State/province [22] 0 0
Kure-shi
Country [23] 0 0
Japan
State/province [23] 0 0
Osaka-shi
Country [24] 0 0
Japan
State/province [24] 0 0
Shinjuku-ku
Country [25] 0 0
Malaysia
State/province [25] 0 0
Johor Bahru
Country [26] 0 0
Malaysia
State/province [26] 0 0
Kota Bharu
Country [27] 0 0
Malaysia
State/province [27] 0 0
Kota Kinabalu
Country [28] 0 0
Malaysia
State/province [28] 0 0
Kuala Lumpur
Country [29] 0 0
Malaysia
State/province [29] 0 0
Kuching
Country [30] 0 0
Mexico
State/province [30] 0 0
Mexico City
Country [31] 0 0
Romania
State/province [31] 0 0
Bucharest
Country [32] 0 0
Romania
State/province [32] 0 0
Cluj Napoca
Country [33] 0 0
Romania
State/province [33] 0 0
Timisoara
Country [34] 0 0
Slovakia
State/province [34] 0 0
Kosice
Country [35] 0 0
Slovakia
State/province [35] 0 0
Nitra
Country [36] 0 0
Slovakia
State/province [36] 0 0
Presov
Country [37] 0 0
Slovakia
State/province [37] 0 0
Trnava
Country [38] 0 0
South Africa
State/province [38] 0 0
Cape Town
Country [39] 0 0
South Africa
State/province [39] 0 0
Milnerton
Country [40] 0 0
South Africa
State/province [40] 0 0
Plumstead
Country [41] 0 0
Spain
State/province [41] 0 0
Madrid
Country [42] 0 0
Spain
State/province [42] 0 0
Sevilla
Country [43] 0 0
Sweden
State/province [43] 0 0
Linköping
Country [44] 0 0
Sweden
State/province [44] 0 0
Stockholm
Country [45] 0 0
Taiwan
State/province [45] 0 0
Kaohsiung
Country [46] 0 0
Taiwan
State/province [46] 0 0
New Taipei City
Country [47] 0 0
Taiwan
State/province [47] 0 0
Taichung
Country [48] 0 0
Taiwan
State/province [48] 0 0
Taipei
Country [49] 0 0
Taiwan
State/province [49] 0 0
Taoyuan
Country [50] 0 0
Turkey
State/province [50] 0 0
Ankara
Country [51] 0 0
Turkey
State/province [51] 0 0
Antalya
Country [52] 0 0
Turkey
State/province [52] 0 0
Bursa
Country [53] 0 0
Turkey
State/province [53] 0 0
Istanbul
Country [54] 0 0
Turkey
State/province [54] 0 0
Izmir
Country [55] 0 0
Turkey
State/province [55] 0 0
Izmit
Country [56] 0 0
Turkey
State/province [56] 0 0
Malatya
Country [57] 0 0
Ukraine
State/province [57] 0 0
Chernivts?
Country [58] 0 0
Ukraine
State/province [58] 0 0
Kiev
Country [59] 0 0
Ukraine
State/province [59] 0 0
Kyiv
Country [60] 0 0
Ukraine
State/province [60] 0 0
Ternopil
Country [61] 0 0
Ukraine
State/province [61] 0 0
Vinnytsia
Country [62] 0 0
Vietnam
State/province [62] 0 0
Hanoi
Country [63] 0 0
Vietnam
State/province [63] 0 0
Ho Chi Minh city
Country [64] 0 0
Vietnam
State/province [64] 0 0
Ho Chi Minh

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
AstraZeneca
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a randomised, double-blind, parallel group, placebo-controlled Phase IIa study
designed to evaluate the efficacy and safety of AZD7798 in participants with moderate to
severe Crohn's disease.
Trial website
https://clinicaltrials.gov/ct2/show/NCT06450197
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
AstraZeneca Clinical Study Information Center
Address 0 0
Country 0 0
Phone 0 0
1-877-240-9479
Fax 0 0
Email 0 0
information.center@astrazeneca.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT06450197